Advanced Tissue Sciences' TransCyte
This article was originally published in The Gray Sheet
Executive SummaryBioengineered human skin was approved in 1997, not 1996 as was reported in "The Gray Sheet" (April 26, p. 7). In addition, the firm's Dermagraft product, not TransCyte, is approved in the U.K. and Canada as a treatment for diabetic foot ulcers
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.